PHARMACOLOGICAL INHIBITION OF MEK CAN IMPROVE OUTCOMES OF HYPERTROPHIC CARDIOMYOPATHY (HCM) IN INDIVIDUALS WITH NOONAN SYNDROME WITH MULTIPLE LENTIGINES (NSML)

PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION

IGFBP7 RATIO FOR HFpEF

BIOMARKERS

PRESCRIPTION OF REMOTE PATIENT MANAGEMENT BASED ON BIOMARKERS

NOVEL METHOD FOR DETERMINING A CONCENTRATION OF N-TERMINAL PRO-HORMONE BNP (NT-PROBNP) IN A SAMPLE

LATERAL FLOW ASSAY TEST STRIPS AND SYSTEMS, AND METHODS OF USE THEREOF

METHOD OF USING TEMPORAL ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY AND MACHINE LEARNING FOR BIOSENSING

MOLECULES FOR DETECTION OF BIOMARKERS IN BODILY EMISSIONS

CMYBPC MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION

METHODS AND RELATED ASPECTS FOR DETECTING AND QUANTIFYING AMOUNTS OF N-TERMINAL PROHORMONE B-TYPE NATRIURETIC PEPTIDE IN WHOLE BLOOD SAMPLES

METHODS AND RELATED ASPECTS FOR PERFORMING LABEL-FREE SINGLE-MOLECULE IMMUNOASSAYS

DEVICES AND METHODS FOR THE DETECTION OF proBNP

DIAGNOSTIC ASSAY USING MAGNETIC PARTICLES

COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE

NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES

PCT MARKER PANELS FOR EARLY DETECTION OF SEPSIS

PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION

BRAIN NATRIURETIC PEPTIDE APTAMER FLUORESCENCE DETECTION DEVICE BASED ON SMART PHONE AND SENSING METHOD OF SAME

METHOD OF PROGNOSIS

METHOD FOR PROGNOSIS

HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNP

CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION

ANTIBODIES BINDING SPECIFICALLY TO NT-PROBNP AND USE THEREOF

ASSESSING AND TREATING ACUTE DECOMPENSATED HEART FAILURE

METHOD FOR PREVENTING, TREATING OR DELAYING HEART FAILURE BY USING NEUREGULIN, AND COMPOSITION

TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION

Antigen analogue for calibration of immunometric diagnostic assays

METHOD FOR SELECTING A PATIENT FOR A REPERFUSION THERAPY

Compositions and methods for treating heart failure

PRESCRIPTION OF REMOTE PATIENT MANAGEMENT BASED ON BIOMARKERS

IGFBP7 RATIO FOR HFpEF

METHOD FOR THE DIAGNOSIS OF MACCE IN PATIENTS WHO UNDERWENT GASTROINTESTINAL SURGERY

USE OF NATRIURETIC PEPTIDES TO ASSESS AND TREAT ACUTE KIDNEY INJURY

POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP

Use of GDF-15 in the Diagnosis and Treatment of Frailty and Conditions Associated with Altered Physiological Reserve, Physical Fitness and Exercise Capacity

Highly sensitive particle enhanced assay for the quantification of NT-proBNP

CARDIOTOXICITY ASSESSMENT METHOD

METHODS FOR TARGETED ASSESSMENT AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ACUTE EVENTS AND MORTALITY ASSOCIATED THEREWITH

METHOD FOR MEASURING BRAIN NATRIURETIC PEPTIDE AND KIT FOR MEASURING BRAIN NATRIURETIC PEPTIDE

System and Method for Disease Surveillance and Disease Severity Monitoring for COVID-19

CIRCULATING SPON-1 (SPONDIN-1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION

Reference standard for BNP measurement

CES-2 (CARBOXYLESTERASE-2) FOR THE ASSESSMENT OF AFIB RELATED STROKE

Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure

METHOD OF DETECTING HEART FAILURE, DEVICE FOR DETECTING HEART FAILURE, SANDWICH IMMUNOASSAY METHOD, AND COMBINATION OF ANTIBODIES

BIOMARKERS FOR RISK PREDICTION OF MORTALITY

NT-proANP AND NT-proBNP FOR THE DIAGNOSIS OF STROKE

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

METHOD OF PROGNOSIS

Method of treating acute coronary syndrome

Method for prediction of response to cardiovascular regeneration based on detecting the amount of biomarkers

Method, composition and device for sampling natriuretic peptides in a biological fluid

FATTY ACID BINDING PROTEIN 3 FOR THE ASSESSMENT OF ATRIAL FIBRILLATION (AF)

Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof

BNP (1-32) epitope and antibodies directed against said epitope

Use of IGFBP-7 in the assessment of heart failure

Antibodies recognizing genetic variants of NT-proBNP

Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof

CIRCULATING ESM-1 (ENDOCAN) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND/OR STROKE

SIGNAL BIOMARKERS

MEANS AND METHODS FOR DIFFERENTIATING BETWEEN HEART FAILURE AND PULMONARY DISEASE IN A SUBJECT

Method of treating a vasculopathy in a human subject

NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE

Method of Determining Risk of an Adverse Cardiac Event

Predicting risk of major adverse cardiac events

Biomarkers to improve prediction of heart failure risk

Methods and systems for the detection of analytes

Methods and Compositions for Personalized Medicine by Point-of-Care Devices for FSH, LH, HCG and BNP

Compositions and methods for treating heart failure

BIOMARKERS AND METHODS OF PREDICTION

Methods and Monitoring of Treatment With A DLL4 Antagonist

METHODS AND COMPOSITIONS FOR PERSONALIZED MEDICINE BY POINT-OF-CARE DEVICES FOR BRAIN NATRIURETIC PEPTIDE

ASSAYS FOR HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE, HUMAN PRO B-TYPE NATRIURETIC PEPTIDE AND HUMAN B-TYPE NATRIURETIC PEPTIDE

USE OF FUSION PROTEINS TO IMPROVE THE AVAILABILITY OF ANTIGENIC PEPTIDE EPITOPES IN IMMUNOASSAYS

NT-pro ANP and SFlt-1 For The Differentiation Between Circulatory And Ischemic Events

Methods for assessing differential risk for developing heart failure

Biomarkers for risk prediction of mortality

METHODS AND COMPOSITIONS FOR MONITORING HEART FAILURE

Replacement Therapy for Natriuretic Peptide Deficiencies

TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION

Method for diagnosing sleep apnea by measuring adipsin and betatrophin levels

Systems for immunoassay tests

BNP (1-32) epitope and antibodies directed against said epitope

Use of IGFBP-7 in the assessment of heart failure

Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP

Method, composition and device for sampling natriuretic peptides in a biological fluid

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

Biomarkers and methods for progression prediction for chronic kidney disease

BIOMARKERS TO IMPROVE PREDICTION OF HEART FAILURE RISK

METHODS OF DIAGNOSING ACUTE CARDIAC DISORDERS USING BNP-SP

Assessing renal structural alterations and outcomes

METHODS OF DETERMINATION OF ACTIVATION OR INACTIVATION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AND BRAIN NATRIURETIC PEPTIDE (BNP) HORMONAL SYSTEMS

Pre-eclampsia biomarkers

USE OF SEPRASE FOR DIFFERENTIAL DIAGNOSIS OF ACUTE DYSPNEA

RAPID TESTS FOR INSURANCE UNDERWRITING

Signal biomarkers

ASSESSING RENAL STRUCTURAL ALTERATIONS AND OUTCOMES

NT-proCNP as a biomarker of vascular disorders and pregnancy complication

TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION

NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE

Immunoassay kit for quantification of BNP and proBNP

Long rigid spacers to enhance binding kinetics in immunoassays

METHODS AND COMPOSITIONS FOR MONITORING HEART FAILURE

Low Volume Assay Device Having Increased Sensitivity

Methods and compositions for personalized medicine by point-of-care devices for brain natriuretic peptide

Predicting risk of major adverse cardiac events

PREDICTION OF OUTCOME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure

CONGESTIVE HEART FAILURE BIOMARKERS

Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

NT-proANP and NT-proBNP for the diagnosis of stroke

Methods and monitoring of treatment with a DLL4 antagonist

Prognosis and risk assessment in stroke patients by determining the level of marker peptides

Molecularly imprinted polymers having affinity for natriuretic peptides

Highly sensitive biomarker panels

Predicting risk of major adverse cardiac events

Monitoring method and apparatus

Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems

Method for increasing natriuresis or diuresis by isoforms of brain natriuretic peptide

Immunoassay for quantification of an unstable antigen selected from BNP and proBNP

MATERIALS AND METHODS FOR DIAGNOSIS OF ASTHMA

Detection of degradation products of feline NT-proBNP

Variants of C-type natriuretic peptide

Method for Detecting Cardiac Ischemia via Changes in B-Natriuretic Peptide Levels

NT-pro ANP and SFlt-1 for the differentiation between circulatory and ischemic events

Highly sensitive immunoassay with large particle labels

MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY

Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction

HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS

Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP

Diagnosis of septic complications

Detection of bacterial infections in subjects suffering from dyspnea

Amelioration of heterophile antibody immunosensor interference

PREDICTING RISK OF MAJOR ADVERSE CARDIAC EVENTS

METHOD OF DETERMINING A PREDISPOSITION TO ATRIAL FIBRILLATION (AF) IN A SUBJECT

Monitoring methods and apparatus

Signal biomarkers

Detection of degradation products of canine NT-proBNP

Method for the in vitro diagnosis of stroke

METHODS FOR DIAGNOSING KIDNEY DAMAGE ASSOCIATED WITH HEART FAILURE

DETECTING AND MONITORING LEFT VENTRICULAR HYPERTROPHY AND CONGESTIVE HEART FAILURE BY PROFILING BIOMARKERS

ENDOSTATIN AS A MARKER OF HEART FAILURE

Prognostic biomarkers for the progression of primary chronic kidney disease

Method for the in vitro diagnosis of stroke

Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES

METHODS AND ASSAYS FOR CLASSIFYING FOODSTUFF AND/OR BEVERAGE AND/OR DIET AND/OR NUTRITION REGIMEN AND/OR MEDICAMENT IN VIEW OF AN EFFECT ON THE CARDIOVASCULAR SYSTEM

Methods for diagnosing heart failure and other cardiac diseases

USE OF CARDIAC HORMONES TO ASSESS RISK OF CARDIOVASCULAR COMPLICATION FROM VOLUME OVERLOAD

PREDICTING CARDIOVASCULAR EVENTS AND RENAL FAILURE IN TYPE 1 DIABETICS

HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS

Method for evaluating myocardial ischemic state using blood sample

D-dimer, troponin, and NT-proBNP for pulmonary embolism

Assay for diagnosis of cardiac myocyte damage

Assays for human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide

Biomarkers for insulin sensitizer drug response

Identification of subjects being susceptible to anti-angiogenesis therapy

MULTIMARKER PANEL FOR MONITORING PATIENTS WITH AND WITHOUT OVERT HEART FAILURE

Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

Detection of cardiac markers on a droplet actuator

Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes

Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof

L-FABP, natriuretic peptides, and cardiac troponins in subjects in need of cardiac therapy

METHOD FOR THE IDENTIFICATION OF PATIENTS IN NEED OF THERAPY HAVING MINOR COGNITIVE DISORDERS AND THE TREATMENT OF SUCH PATIENTS

Highly sensitive biomarker panels

Natriuretic peptide receptor-C agonists

Variants of C-type natriuretic peptide

HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS

Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease

USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE

USE OF BNP-TYPE PEPTIDES FOR PREDICTING DIALYSIS NEED

NT-proBNP/troponin ratio for assessing myocardial dysfunction

Natriuretic peptides for diagnosing cardiac complications due to coronary catheterization

Materials and Methods for Diagnosis of Asthma

DIFFERENTIATION OF CAUSES OF RIGHT HEART FAILURE

Amelioration of heterophile antibody immunosensor interference

NATRIURETIC PEPTIDE/GDF-15 RATIO FOR DIAGNOSIS OF CARDIAC DISORDERS

BNP(1-32) epitope and antibodies directed against said epitope

Biochemical markers for acute pulmonary embolism

Immunoassay for quantification of an unstable antigen selected from BNP and proBNP

Making a prognosis in cases of cardiac disease using a combination of markers

Assessing heart failure in patients with atrial fibrillation using GDF-15 and natriuretic peptides

PROGNOSIS AND RISK ASSESSMENT IN PATIENTS SUFFERING FROM HEART FAILURE BY DETERMINING THE LEVEL OF ADM AND BNP

Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP

Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients

Method of determining equine NT-proBNP

Biochemical markers for acute pulmonary embolism

Diagnostic means and methods using troponin T and NT-proBNP

DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE

POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP

ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES

Predicting risk of major adverse cardiac events

Methods of diagnosing acute cardiac disorders using BNP-SP

Method, composition and device for sampling natriuretic peptides in a biological fluid

Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays

Method for detecting cardiac collateral formation

DETERMINING CANINE proBNP

DETERMINING CANINE proBNP

Determining feline proBNP

Determining feline proBNP

NT-proBNP, proBNP AND BNP IMMUNOASSAYS, ANTIBODIES AND STABLE STANDARD

Analytical sandwich test for determining NT-proBNP

IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL

Human BNP immunospecific antibodies

Differentiation of acute and chronic myocardial necrosis in symptomatic patients

Biochemical markers for acute pulmonary embolism

NT-proANP and NT-proBNP for diagnosing cardiac diseases

Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease

USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE

HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS

Methods and compositions for monitoring and risk prediction in cardiorenal syndrome

Method of stabilizing human natriuretic peptides

Compositions comprising human brain natriuretic peptide (BNP) fragments

NATRIURETIC PEPTIDE RATIO FOR DIAGNOSING CARDIAC DYSFUNCTIONS

Human BNP immunospecific antibodies

Cardiac troponin as an indicator of coronary artery disease

Differentiation of cardiac and pulmonary causes of acute shortness of breath

Biomarker fragments for the detection of human BNP

Assessment of skeletal growth using measurements of NT-CNP peptides

Isoforms of brain natriuretic peptide

Methods and compositions for the diagnosis of venous thromboembolic disease

Prognostic Methods for Congestive Heart Failure

Human BNP immunospecific antibodies

Method for measuring the amount of natriuretic peptides in a sample

Diagnosing risk of cardiovascular complications using natiuretic peptides

Identification of canine proBNP by immunoassay

Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems

Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes

Method for detecting cardiac ischemia via changes in b-natriuretic peptide levels

Multimarker panel for diabetes type 1 and 2

Diagnosis of acute myocardial, ischemic diseases

Sandwich immunoassay for identifying partial proANP peptides

Stabilized compositions containing natriuretic peptides

Diagnosis

Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs

Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP

Method for detecting cardiac collateral formation

Diagnostic markers of acute coronary syndrome and methods of use thereof

Method of making stable calibrators or controls for measuring human natriuretic peptides

Multimarker panel for diabetes type 1 and 2

Multimarker panel based on PIGF for diabetes types 1 and 2

Diagnostics based on signal peptide detection

Methods for determining levels of human b-type natriuretic peptide precursors

Use of cardiac hormones to assess risk of cardiovascular complication from volume overload

Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes

Monitoring method and apparatus

Analytical sandwich test for determining NT-proBNP

Stable compositions for measuring human natriuretic peptides

Stable calibrators or controls for measuring human natriuretic peptides

Plasma thermograms for diagnosis and treatment of acute myocardial infarction